Recursion Pharmaceuticals, Inc. ( NASDAQ: RXRX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day on Wednesday, slashing 6.29 percent to close at $4.77 ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

The International Economic Review was established in 1960 by two of the most active and acclaimed scholars in the economics profession: Michio Morishima, who was then at Osaka University's Institute ...

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...

Out of all of the big bombs and format staples Kamigawa: Neon Dynasty introduced, it may seem weird that a land is its best ...

We talk energy efficiency, dataset disclosure, and why new laws may push companies to shut down their AI operations in Europe ...